#SumitomoChemicalCompanyLimited

Sumitomo Pharma, a subsidiary of Sumitomo Chemical, obtained manufacturing and marketing approval on March 6, 2026, for the world's first iPS cell-derived regenerative medicine "Amshepli®". Sales exceeding 100 billion yen are expected in the 2030s.

In the individual financial statements for the third quarter of the fiscal year ending March 2026, an equity method investment loss of 13,361 million yen was recorded. There is no impact on consolidated earnings.

Sumitomo Chemical will allocate 0.87 shares for each share of Tanaka Chemical, and plans to execute the share exchange using approximately 14,028,356 shares of treasury stock.

Sumitomo Chemical has signed a business integration agreement to integrate its domestic polyolefin PP and LLDPE businesses into Prime Polymer Co., Ltd. through a simplified absorption-type company split and will acquire 20% equity in the company.